These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33417509)

  • 41. Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes.
    Zhang H; Wang X; Deng W; Wang S; Ge J; Toft E
    Medicine (Baltimore); 2016 Sep; 95(38):e4820. PubMed ID: 27661023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
    Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial.
    Zocca P; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Hartmann M; Linssen GCM; Doggen CJM; von Birgelen C
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):567-576. PubMed ID: 30143879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials.
    Kobayashi T; Sotomi Y; Suzuki S; Suwannasom P; Nakatani S; Morino Y; Ako J; Kozuma K; Hirayama A; Sakata Y; Higuchi Y
    Cardiovasc Interv Ther; 2020 Jul; 35(3):250-258. PubMed ID: 31422529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
    Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current status of drug-eluting stents.
    Räber L; Windecker S
    Cardiovasc Ther; 2011 Jun; 29(3):176-89. PubMed ID: 20370793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.
    Bangalore S; Toklu B; Patel N; Feit F; Stone GW
    Circulation; 2018 Nov; 138(20):2216-2226. PubMed ID: 29945934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds.
    Waksman R
    Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e20-e24. PubMed ID: 29281608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials.
    Philip F; Stewart S; Southard JA
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):38-48. PubMed ID: 26916633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Current Literature on Bioabsorbable Stents: a Review.
    Omar WA; Kumbhani DJ
    Curr Atheroscler Rep; 2019 Nov; 21(12):54. PubMed ID: 31768641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study.
    Tang XF; Ma YL; Song Y; Xu JJ; Yao Y; He C; Wang HH; Jiang P; Jiang L; Liu R; Gao Z; Zhao XY; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ
    Cardiovasc Diabetol; 2018 Aug; 17(1):114. PubMed ID: 30107794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients.
    Lupi A; Rognoni A; Secco GG; Lazzero M; Nardi F; Fattori R; Bongo AS; Agostoni P; Sheiban I
    Eur J Prev Cardiol; 2014 Apr; 21(4):411-24. PubMed ID: 23152364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
    Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
    Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy.
    Partida RA; Yeh RW
    Cardiol Clin; 2017 May; 35(2):281-296. PubMed ID: 28411902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
    Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.